Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 7, 2010

Pfizer to Re-Test Failed Melanoma Drug in Phase III with Debiopharm

  • Pfizer has signed on Debiopharm Group to evaluate its melanoma drug candidate tremelimumab, which previously failed in Phase III. The companies’ co-development agreement for tremelimumab has Debiopharm responsible for the trial, while Pfizer retains rights to worldwide commercialization.

    An interim analysis done on tremelimumab, a fully human anti-CTLA4 mAb, during its last Phase III development program found that it would not offer any benefit over standard chemotherapy. Thus in April 2008, Pfizer was forced to halt the trial.

    A full evaluation of the data revealed a biomarker that predicted patients who were more likely to respond. The Phase III study to be conducted by Debiopharm will leverage this marker to select patients with unresectable, stage IV melanoma for enrollment.

     



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »